AVH 6.83% $2.73 avita medical inc.

a feasibility study of the recell® autologous , page-11

  1. 528 Posts.
    you can see why it had a value of $6 a share back 7 years ago before old management tried to do back door sales without approval and burnt the reputation of the company.

    however new management do seem to be doing the right things. all it takes is google search for "recell" and you will see a growing list of plastic surgery practices around the world now offering recell as well as real people giving there experiences with the product.

    The article about the ulcers on the "in the news" section of avitas website did look extremely promising. With 10% completely healing and the other 90% showing a 55% reduction in ulcer size. Like coppa said, big market the ulcer market and it is growing with the worlds ageing population.


 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.